ATE329263T1 - Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha - Google Patents

Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha

Info

Publication number
ATE329263T1
ATE329263T1 AT99971513T AT99971513T ATE329263T1 AT E329263 T1 ATE329263 T1 AT E329263T1 AT 99971513 T AT99971513 T AT 99971513T AT 99971513 T AT99971513 T AT 99971513T AT E329263 T1 ATE329263 T1 AT E329263T1
Authority
AT
Austria
Prior art keywords
heavy chain
light chain
alpha
antibody
variable
Prior art date
Application number
AT99971513T
Other languages
English (en)
Inventor
Jonathan L Miller
Original Assignee
Jonathan L Miller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jonathan L Miller filed Critical Jonathan L Miller
Application granted granted Critical
Publication of ATE329263T1 publication Critical patent/ATE329263T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99971513T 1998-10-30 1999-10-29 Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha ATE329263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10627598P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
ATE329263T1 true ATE329263T1 (de) 2006-06-15

Family

ID=22310524

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971513T ATE329263T1 (de) 1998-10-30 1999-10-29 Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha

Country Status (8)

Country Link
EP (1) EP1051620B1 (de)
JP (1) JP2002529054A (de)
AT (1) ATE329263T1 (de)
AU (1) AU1458500A (de)
CA (1) CA2317808A1 (de)
DE (1) DE69931756T2 (de)
IL (1) IL137121A0 (de)
WO (1) WO2000026667A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918788D0 (en) 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
DE10019967A1 (de) * 2000-04-20 2001-10-25 Fenning Biomed Gmbh Dr Antikörper gegen natives gp96, deren Herstellung und Verwendung
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1539236A4 (de) * 2002-07-03 2007-07-18 Univ Pennsylvania Zusammensetzungen, verfahren und kits in verbindung mit anti-blutplättchen-autoantikörpern und inhibitoren davon
AU2003298112A1 (en) * 2002-11-13 2004-06-03 Micromet Ag Method for identifying antigen specific b cells
RU2006102570A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Антитела и их применение
EP1749536A1 (de) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Aktivierte Stimulatoren des Faktors X als antihämorrhagisches Mittel für die topische Anwendung
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2186829B1 (de) * 2008-11-14 2014-12-31 Canadian Blood Services Antikörper gegen GPIbalpha
CN102905727B (zh) * 2009-10-30 2016-12-07 詹森生物科技公司 Il-17a拮抗剂
KR20220127250A (ko) * 2019-12-10 2022-09-19 씨씨오에이 테라퓨틱스 (항저우) 컴퍼니 리미티드 인간화 항-당단백질 ib알파(gpibalpha) 항체
US20230055143A1 (en) * 2019-12-20 2023-02-23 Medimmune, Llc Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3
WO2021262880A2 (en) * 2020-06-23 2021-12-30 Kadmon Corporation, Llc Anti-pd-1 antibodies and fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
US5817748A (en) * 1995-03-17 1998-10-06 The Research Foundation Of State University Of New York Mimotopes of human Platelet glycoprotein Ib/IX

Also Published As

Publication number Publication date
WO2000026667A1 (en) 2000-05-11
EP1051620A1 (de) 2000-11-15
JP2002529054A (ja) 2002-09-10
WO2000026667A9 (en) 2001-04-12
AU1458500A (en) 2000-05-22
CA2317808A1 (en) 2000-05-11
DE69931756T2 (de) 2007-05-24
DE69931756D1 (de) 2006-07-20
IL137121A0 (en) 2001-06-14
EP1051620A4 (de) 2005-01-12
EP1051620B1 (de) 2006-06-07

Similar Documents

Publication Publication Date Title
ATE329263T1 (de) Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
SE9201331D0 (sv) Protein l och hybridproteiner daerav
HRP20090517T1 (hr) Protutijela na interleukin-10
DK0527839T3 (da) Rekombinant bibliotekscreeningsfremgangsmåder
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
CR7343A (es) Anticuerpos para cd40
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
NO961151D0 (no) Antistoffer mot CD40
DE69434286D1 (de) Immunologische bestimmungen von prostata-spezifischem antigen
MX9602971A (es) Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos.
DK0640135T3 (da) Immunoglobulinbindende proteiner, der er afledt af protein L, og anvendelser af disse
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
ATE161582T1 (de) Monoklonale antikörper der maus
DE50115580D1 (de) Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
ATE332914T1 (de) Mimotope und antimimotope des menschlichen plättchen-glykoproteins ib/ix
FR2560212B1 (fr) Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
DE69927668D1 (de) Massenfingerabdrucken und seiner verwendung zur identifizierung von protein-affinitätsliganden
NZ512332A (en) Potassium channel interactors and uses therefor
ATE374819T1 (de) Antagonistischer antikörper gegen pro842
SE9500148D0 (sv) Antibodies for use in cancer therapy and diagnosis
KR950016780A (ko) 신규 모노클로날 항체

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties